Real-world effectiveness of tirzepatide in individuals with obesity: weight response, treatment-related factors and diabetes status
Authors' conclusion
Tirzepatide was effective and well tolerated in routine practice. Greater weight loss occurred in obesity without T2D, while prior GLP-1RA exposure was independently associated with a reduced weight response. Previous GLP1-RA exposure may partly account for the different weight-loss trajectories observed between obesity with and without T2D. Residual differences at longer follow-up may reflect additional unmeasured clinical, metabolic, and treatment-related factors.
Study context
- Population
- Adults with overweight/obesity without T2D (Ob) or with T2D (ObT2D) treated with tirzepatide
- Participants
- 210 vs 378
- Exposure
- Ob vs ObT2D
- Obn = 210
- ObT2Dn = 378
- Outcome
- Weight loss
- Follow-up
- T1 (2-4 months), T2 (5-8 months), T3 (9-15 months)
Main finding
As reported in the abstract
Ob vs ObT2D at T1
−5.0% vs −2.8%
Ob vs ObT2D at T2
−10.1% vs −3.3%
Ob vs ObT2D at T3
−14.2% vs −4.7%
Observational data: associations, not effects.
Further findings
Baseline characteristics
Female
Previous GLP-1RA exposure
P < 0.001
Weight loss restricted to treatment-naïve participants
- Difference attenuated and no longer statistically significant
Prior GLP-1RA exposure and weight loss
- Prior GLP-1RA exposure independently associated with lower weight loss
- Interaction between prior GLP-1RA exposure and T2D status emerged at longer follow-up
- No effect modification by sex or age clearly detectable
Discontinuation
- Discontinuation more frequent in Ob, with adverse events and financial barriers among the main reported reasons
Baseline characteristics
- Ob participants were younger, had higher BMI, better glycemic control
Safety
Adverse events
P < 0.001
- Adverse events — Adverse events overall
- 16.9%
Adverse events
- Mainly mild, transient gastrointestinal events
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →